The goal of breast cancer screening has always been straightforward: find it early, when it’s most treatable. When it’s confined to a small area of the breast, five-year survival rates exceed 99%. When it has spread to distant organs — what doctors call Stage 4 or metastatic breast cancer — that figure drops to around 29%.
Which is why a pair of new studies, covered recently by Radiology Business and published in major peer-reviewed journals, should prompt serious attention. The data shows that across the United States, more people are reaching their first breast cancer diagnosis already at Stage 4. Not just among a specific demographic. Not just in a specific region. Across virtually every group studied — age, race, ethnicity, tumor subtype, and even among men — the trend is moving in the wrong direction.
This isn’t a crisis of treatment. Survival outcomes have actually improved significantly over the same period, reflecting genuine advances in therapeutics. This is a crisis of detection. And understanding it requires looking honestly at what the numbers say, what might be driving them, and what the evidence tells us about how to respond.
The Numbers: What Two Major Studies Found
The first study, published in Radiology Imaging Cancer in May 2025, analyzed data from the Surveillance, Epidemiology, and End Results (SEER) program — one of the most comprehensive cancer databases in the United States, covering data from registries that represent nearly half the U.S. population. Researchers examined distant-stage (metastatic) breast cancer incidence rates from 2004 to 2021, covering up to 80 million women annually.
The findings were unambiguous: distant-stage breast cancer incidence increased significantly over the entire study period, with an overall annual percentage change of 1.16%. That may sound modest, but compounded over 17 years, it represents a substantial and statistically meaningful upward trend.
| +1.16% Annual rise in distant-stage diagnoses overall (2004–2021) | +2.91% Annual rise among women aged 20–39 — the steepest increase | +3.86% Annual rise in Native American women — highest by ethnicity | +3.7% Annual rise among men — a notable and underreported finding |
A second study, from Dana-Farber Cancer Institute, published in JAMA Network Open in May 2026, reinforced these findings from a slightly different angle. Researchers analyzed 761,471 breast cancer diagnoses from SEER between 2010 and 2021. They found that Stage IV breast cancer incidence rose from 9.5 cases per 100,000 women in 2010 to 11.2 cases per 100,000 women in 2021 — an increase of 1.2% per year, slightly faster than the overall breast cancer incidence rate of 1% per year. Critically, the Stage IV increase was statistically significant across all age groups, all racial groups, and all tumor subtypes.
“It’s important to understand that these women presented with distant (metastatic or Stage 4) breast cancer at the time of diagnosis. Women with this diagnosis have a much lower survival rate and are much harder to treat.”
— Dr. Debra L. Monticciolo, MD, past president of the American College of Radiology, co-author of the SEER study
Who Is Most Affected
The breadth of the trend across demographic groups is one of its most troubling features. This isn’t a story about one underserved population being failed by the healthcare system — though disparities do exist and matter. It’s a story about a system-wide shift in how breast cancer is presenting at first diagnosis.
Age: Younger Women Showing the Steepest Rise
Women aged 20 to 39 showed the highest annual percentage increase in distant-stage diagnoses at 2.91% per year from 2004 to 2021 — more than double the overall rate. This is particularly striking because young women are typically considered lower-risk for breast cancer and are not routinely included in standard screening protocols that begin at 40. It raises questions about whether current screening guidelines are adequately protecting younger women who develop fast-growing cancers between scheduled exams, or before they’re eligible for screening at all.
Race and Ethnicity: Disparities Persist and Widen
The racial picture is complex and deeply concerning. Native American women had the highest annual percentage change in metastatic diagnoses at 3.86% (or 3.9%, depending on the dataset and time period analyzed). Asian women followed at 2.90% annually. Hispanic women showed an increase of 1.56% per year.
These numbers sit against a backdrop of longstanding structural disparities in breast cancer care. Minority women — particularly Black women — face higher mortality rates from breast cancer despite lower or comparable incidence rates compared to white women, a gap driven by later-stage diagnoses, unequal access to screening, and differences in healthcare utilization. The SEER study’s findings suggest this picture isn’t improving on its own.
Disparities at a Glance
- Native American women: 3.86–3.9% annual increase in metastatic diagnoses — the steepest of any group
- Asian women: 2.90% annual increase in metastatic diagnoses
- Hispanic women: 1.56% annual increase; breast cancer less likely to be caught at localized stage than in non-Hispanic white women
- Black women: breast cancer mortality remains 37% higher than white women despite lower incidence
- During COVID-19: “steep drops” in older and minority women being screened, per ACR researchers
Men: A Statistically Significant and Underreported Finding
Breast cancer in men is rare — but it is increasing. The Radiology Business report noted that the annual percentage change in late-stage diagnoses among men was 3.7%, making it one of the steepest increases in the dataset. Breast cancer in men is already frequently diagnosed late because awareness is low, self-monitoring is rare, and clinical protocols are not designed with male patients in mind. The rising trend among men is a reminder that this is not exclusively a women’s health issue — and that the gaps in awareness have real consequences.
The COVID Factor — Real, but Not the Whole Story
It would be tempting to attribute the entire trend to COVID-19 pandemic disruptions. The pandemic did cause a sharp and well-documented decline in breast cancer screening: radiology volumes fell significantly in 2020 and 2021, and minority and older women were disproportionately affected by the screening gaps. Researchers specifically noted “steep drops in the number of older, minority women being screened” during that period.
But the trend in late-stage diagnoses began long before the pandemic. The SEER data analyzed in the first study runs from 2004 to 2021 — and the upward slope was present throughout, not just from 2020 onward. The COVID disruption likely accelerated or amplified a trend already in motion, rather than creating it.
The deeper question — what was driving late-stage presentations even before 2020 — remains open. Researchers have identified several candidate explanations, and the honest answer is that it’s probably more than one factor.
What Might Be Driving It: A Complicated Picture
The rise in late-stage diagnoses exists alongside, and in tension with, several other trends. Screening rates in the U.S. have generally remained stable or improved over the same period. Early-stage breast cancer diagnoses have also been rising. Treatment outcomes are better than ever. So why are more people arriving at first diagnosis already at Stage 4?
Suboptimal Screening Participation
Despite overall stability in screening rates, participation remains uneven. Nearly half of women surveyed in a recent study still believed breast cancer screening begins at age 50 — a misunderstanding with real consequences given that major organizations now recommend starting annual mammography at 40. Screening guidelines from different bodies (the American College of Radiology, the U.S. Preventive Services Task Force, the American College of Physicians) differ meaningfully, creating confusion that translates into delayed or skipped screenings.
Interval Cancers and Screening Limitations
Not all cancers that are caught late were missed due to lack of screening. Some are what clinicians call “interval cancers” — tumors that develop and progress to an advanced stage between scheduled screening appointments. Fast-growing cancers, particularly in younger women with denser breast tissue, can reach metastatic stage within months. Standard annual mammography, while effective for many cancer types, does not catch every case before it spreads.
The Mammography False-Negative Problem
A separate study analyzing over 38 million mammograms in the National Mammography Database found that mammography false-negative rates have been rising — meaning cancers present in the breast were not identified on imaging. Researchers identified several contributing factors, including increasing use of supplemental screening (breast MRI or ultrasound), which may be exposing the limitations of mammography for certain cancer types, particularly invasive lobular breast cancer, which is frequently invisible on mammograms.
Access and Structural Barriers
For many women — particularly those without insurance, those in rural areas, or those in communities with historically poor relationships with the healthcare system — late-stage diagnosis reflects not a failure of imaging technology but a failure to access it at all. Structural barriers to screening are well-documented and have not been solved.
The Biology of Breast Cancer Itself May Be Changing
Perhaps most intriguingly, some researchers have raised the possibility that the natural history of breast cancer itself may be shifting. Breast cancer incidence has been rising at 1% per year since the mid-2000s, driven in part by rising obesity rates and changing fertility patterns. Whether these biological shifts are also producing cancers that are more aggressive or more likely to present at advanced stages is an active area of investigation.
The Silver Lining — and Why It Doesn’t Erase the Problem
Both studies noted something that is genuinely encouraging: overall survival from breast cancer improved over the same period studied. The U.S. breast cancer death rate has declined 44% from its 1989 peak through 2023, averting an estimated 546,000 deaths. Stage IV survival specifically has improved, reflecting major advances in targeted therapies, immunotherapy, and precision oncology.
But the researchers are careful not to let this good news obscure the bad. Survival improvements for Stage IV patients are real — but they come at enormous cost. Metastatic breast cancer treatment is expensive, prolonged, and physically demanding. It’s estimated that around 168,000 breast cancer survivors in the U.S. are currently living with Stage 4 disease. Better treatments mean more people living with advanced cancer, not fewer people reaching that stage in the first place.
“These findings underscore the need to better understand drivers of advanced-stage cancer presentation and to develop strategies to reduce the burden of metastatic disease at diagnosis.”
— Study authors, JAMA Network Open / Dana-Farber Cancer Institute, 2026
Treating Stage 4 cancer is not the same as preventing it. And the data is clear that on the prevention side — catching breast cancer before it spreads — the trend is heading in the wrong direction.
What the Research Is Calling For
Both studies end with a version of the same conclusion: we need to understand the drivers better, and we need strategies to intervene earlier. That’s partly a call for more research — but it’s also a practical message about the tools already available.
What the Evidence Supports
The American College of Radiology recommends annual mammography starting at age 40 for women at average risk. For women at higher risk — due to dense breast tissue, family history, or genetic factors — supplemental screening with breast ultrasound or MRI is recommended. Studies consistently show that supplemental ultrasound screening detects additional cancers in women with dense breasts that mammography misses entirely. Despite this evidence, many women are not informed of their breast density and do not receive supplemental screening.
For populations with elevated cancer risk — including first responders, who face occupational carcinogen exposures that increase baseline cancer risk across multiple cancer types — the case for proactive, comprehensive screening programs is especially strong. Getting ahead of cancer at Stage 1 or 2, rather than catching it at Stage 4, isn’t just a better health outcome. It’s a fundamentally different life experience.
The ultrasound-based screening programs available through UDS Health are specifically designed to extend detection capabilities beyond what standard primary care offers — providing comprehensive imaging for high-risk populations who may otherwise fall through the cracks of a system where guidelines conflict, screening access is uneven, and the consequences of a missed or delayed diagnosis can be severe.
The Broader Message
The data from these studies isn’t a reason for despair — but it is a reason to act. The science of breast cancer treatment has never been better. The tools for early detection — mammography, supplemental ultrasound, MRI — have never been more capable. And yet more people are arriving at diagnosis at the hardest-to-treat stage of the disease.
That gap between what’s possible and what’s happening in practice is the problem these studies are pointing at. It won’t be solved by any single policy change or technological breakthrough. It will be solved by consistent, proactive engagement with screening — particularly for the groups this data shows are falling furthest behind.
Early detection programs built around high-risk populations are part of the answer. So is clear, accessible public communication about when to screen, how often, and why it matters. And so is the honest reckoning with the fact that the current system, for too many people, is not working — not because the tools don’t exist, but because access to them remains unequal, inconsistent, and too often dependent on whether a patient already knows to ask.
The most important number in breast cancer isn’t the five-year survival rate for Stage 4. It’s the 99%+ survival rate for Stage 1. Every diagnosis that happens earlier instead of later is a life materially changed. The research is telling us we’re moving in the wrong direction on that front — and that the time to course-correct is now.
Sources: Hendrick RE, Monticciolo DL, et al. “Rising Rates of Distant-Stage Breast Cancer: Trends Among U.S. Women.” Radiology Imaging Cancer, May 2025. DOI: 10.1148/rycan.259012 | Leone JP, et al. Dana-Farber Cancer Institute. JAMA Network Open, May 2026 | Original reporting: Radiology Business | Supporting data: Susan G. Komen 2026 Progress Outlook; National Breast Cancer Foundation 2026 Statistics
